The incidence of these relatively rare tumors is rising as more mesenchymal tumors are now being tested for the C-Kit protein (CD117) which is one of the characteristic immunological markers that these lesions express [3]. The gene discussed is KIT; the disease is mesenchymal cell neoplasm.